Site Logo

OUR PLATFORM

With our innovative protein-engineering technology, we transform proteins into material-binding variants

Video PlayWatch Video
OUR PLATFORM OUR PLATFORM
OUR INNOVATION

Our computational platform converts recombinant proteins into material-binding variants that can be used to coat implants, devices, and injectable carriers. This novel and unprecedented method enables us to deliver therapeutics to any location in the body with precision.

Technology Overview

  • NATIVE PROTEIN

    Proteins in nature did not evolve specifically to treat diseases. Most proteins administered as therapeutics to patients have suboptimal properties for treating the target disease.

    Technology Image 0
  • PROPRIETARY SEQUENCE OPTIMIZATION

    With a combination of computational and in vitro methods we are able to identify variants that have valuable material binding properties.

    Technology Image 1
  • MATERIAL-BINDING VARIANTS

    The output of this process is a novel protein variant that preserves native biological function and that can bind to the selected material with extremely high affinity. This enables new therapeutics that are safer and more effective.

    Technology Image 2
REDEFINING REGENERATIVE MEDICINE FIELD
BENEFITS OF MATERIAL-BINDING PROTEINS
ONE-STEP SURFACE COATING

Our modified proteins can be applied easily in a simple one-step process that does not require any chemical modification.

One Step Surface Coating One Step Surface Coating
BINDING WITH ANY CARRIER

Our material-binding proteins can be used to coat implants, devices, and injectable carriers.

Carriers coated with our modified proteins enable long-term local delivery with vastly reduced off target effects.

  • Carrier-0
  • Carrier-1
  • Carrier-2
  • Carrier-3
“The fact that living tissues don’t currently integrate well with implanted materials is one of the main hurdles in surgical treatment and replacement of tissue functions through foreign materials.”
Harald Ott
Surgeon and tissue engineering researcher at Massachusetts General Hospital
VALUABLE IP

Every protein we generate with our method is novel composition of matter, thus creating unique and independent IP.

ADDRESSING UNMET PATIENTS NEEDS
OUR FOCUS AREAS

We are focusing on previously out-of-reach clinical indications in vascular, soft tissue, and orthopedic repair as well as targeted chemotherapeutics and have already demonstrated superiority over standard of care in all preclinical studies conducted to date, including studies at the Cleveland Clinic and Mayo Clinic.

VASCULAR, SOFT TISSUE & ORTHOPEDIC REPAIR VASCULAR, SOFT TISSUE & ORTHOPEDIC REPAIR
VASCULAR, SOFT TISSUE & ORTHOPEDIC REPAIR
LEARN MORE
PARTNER WITH US

We are headquartered in Frederick, Maryland with other locations in Boston, Orlando, and Memphis.

We believe in the power of teams and have several partnerships that are advancing new therapies. If you are interested in exploring a partnership, contact us.